Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Data: Total single-day net inflow of US XRP spot ETFs reaches $13.7446 million

Data: Total single-day net inflow of US XRP spot ETFs reaches $13.7446 million

ChaincatcherChaincatcher2026/04/18 00:33
Show original

According to ChainCatcher, citing SoSoValue data, yesterday (April 17, Eastern Time) the total daily net inflow into XRP spot ETFs was 13.7446 million US dollars.

Among them, the Bitwise XRP ETF (XRP) recorded a single-day net inflow of 10.8055 million US dollars, with a cumulative historical net inflow reaching 417 million US dollars. The 21Shares XRP ETF (TOXR) saw a single-day net outflow of 289,800 US dollars, with total historical net outflow reaching 20.7002 million US dollars.

As of press time, the total net asset value of XRP spot ETFs is 1.115 billion US dollars, with the XRP net asset ratio at 1.22%, and the cumulative historical net inflow reaching 1.275 billion US dollars.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

Tradr ETFs announced that its two leveraged products linked to SK Hynix ADRs will be liquidated and delisted around November 12, with one being long and the other short. Despite only being listed for a few months, their combined scale has shrunk to about $1.3 million, down more than 60% from their peak. SK Hynix's Seoul stock price has fallen 56% from its high, similar products in the industry are generally under pressure, and South Korea has also further tightened regulations on leveraged products.

华尔街见闻•2026/10/26 05:56
Just about three months after listing, two SK Hynix leveraged ETFs are set to be delisted in the United States.

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.